Meet the faculty
Program Director
Fernando Lopez-Rios
Director, Molecular Diagnostics Service, Hospital Universitario 12 de Octubre, Madrid, Spain
Fernando Lopez-Rios has recently joined the Department of Pathology at “12 de Octubre” University Hospital (Madrid) as the Chief of the Molecular Diagnostics Service. He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University respectively and completed his residency in Pathology at “12 de Octubre” University Hospital (Madrid). Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at “HM Hospitales” and a visiting researcher at Memorial Sloan Kettering Cancer Center (USA). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is currently a member of the IASLC Pathology Committee.
Disclosures:
Grants/research support: Lilly, Roche, Thermo Fisher Scientific
Honoraria or consultation fees: Lilly, Roche, Thermo Fisher Scientific, Astra Zeneca, Bayer, Takeda, Janssen, MSD, BMS, Pfizer
Alexander Drilon
Chief, Early Drug Development,
Memorial Sloan Kettering Cancer Center, New York, USA
Dr. Alexander Drilon is the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York. His research focuses on the development of targeted therapy for genomic subsets of lung cancer and other solid tumors, including cancers that harbor fusions involving ALK, ROS1, RET, and NTRK1/2/3, and MET exon 14 skipping alterations. He is a recipient of American Society for Clinical Oncology (ASCO)/Conquer Cancer Foundation Career Development and Young Investigator Awards, and grants from the International Association for the Study of Lung Cancer and the Lung Cancer Research Foundation. Dr. Drilon is also a member of the Editorial Board of ASCO University.
Disclosures:
Honoraria/advisory boards: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, I3 Health, MonteRosa, Innocare, Boundless Bio
Equity: Treeline Bio
Associated research paid to institution: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar
Copyright: Selpercatinib-Osimertinib (filed/pending)
Research: Foundation Medicine
Royalties: Wolters Kluwer
Other (food/beverage): Merck, Puma, Merus, Boehringer Ingelheim
CME honoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, Remedica Ltd., Lungevity.
Caterina Marchiò
Associate Professor of Pathology,
University of Turin, Italy
Dr. Caterina Marchiò is an Experimental Pathologist leading the Research Program of the Pathology Unit at the Candiolo Cancer Institute.
Dr. Marchiò is devoted to deconvoluting the complexity of Pathology to foster precision medicine. She is also actively involved in the standardization of preanalytical conditions of tissue sample management and processing, to guarantee quality of DNA, RNA and antigens.
She has been involved in the ESMO Translational Research and Precision Medicine Working Group and led the consensus recommendation paper on the standard methods to detect NTRK fusions in daily practice and clinical research.
Disclosures:
Honoraria or consultation fees: Bayer, Roche, Daiichi Sankyo, AstraZeneca
Nicolas Girard
Professor of Respiratory Medicine,
Versailles Saint Quentin University, Paris Saclay, Paris, France
Nicolas Girard is a pneumologist specializing in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. He is domain leader for rare thoracic cancers for the European Reference Network EURACAN. Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. He is also the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Department at Institut Curie in Paris. Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.
Disclosures:
Research grants/support from: Abbvie, Amgen, AstraZeneca, Beigene, Boeringer Ingelheim, Bristol Myers Squib, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Sanofi, Sivan.
Consultative services for: Abbvie, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Sharpe & Dohme, Mirati, Novartis, Pfizer, Pierre Fabre, Sanofi, Sivan Takeda.
Participation on a data safety monitoring board for Hoffmann-La Roche.
Employment of a family member with AstraZeneca.
Xiuning Le
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
As an Associate Professor and Deputy Section Chief in the Thoracic/Head and Neck department Dr. Le has contributed her knowledge via trials, clinical journals and lectures with focus non-small cell lung cancer with actionable oncogenes.
Dr. Le earned her medical degree from the Peking Union Medical College. She then went on to earn a degree in Biological and Biomedical Sciences at Harvard Medical School in Boston. She completed her internship and residency at The University of Massachusetts Medical Center in Worcester, MA, an additional residency at the University of Texas. Prior to joining the staff at M.D. Anderson, she also completed a fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Board certified in both internal medicine and medical oncology, Dr. Le specializes in thoracic, head, and neck oncology.
Dr. Le has led clinical trials resulted in FDA approval of novel targeted therapies in lung cancer. She has published more than 120 articles in the field of lung and head and neck cancer. She was first- or last author of many high-impact papers, including New England Journal of Medicine, Cancer Discovery, Clinical Cancer Research and Journal of Thoracic Oncology.
Dr. Le received the ASCO Young Investigator Award, SU2C-TVF Convergence Program, Claudia Adams Barr for Innovative Cancer Research, ASCO Career Development Award, Paul Calabresi NIH K12 Award, Damon Runyon Award, V Foundation Award, and Sabin Award, and more.
Disclosures:
Consulting/advisory fees: Eli Lilly, EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Regeneron, Boehringer Ingelheim, Hengrui Therapeutics, Bayer, Teligene, Taiho, Daiichi Sankyo, Janssen, Blueprint Medicines, Sensei Biotherapeutics, SystImmune, ArriVent, Abion, and Abbvie.
Research Funding to Institution: Eli Lilly, EMD Serono, ArriVent, Dizal, Teligene, Regeneron, Janssen, ThermoFisher, Takeda, and Boehringer Ingelheim.
Travel support: EMD Serono, Janssen, and Spectrum Pharmaceutics.
Stock options: BlossomHill
Alex Miles
Police Officer and Patient
Alex has worked in law enforcement in the UK for almost 25 years. He is husband to his beautiful wife and father to four wonderful children. He loves exercise and fitness and his hobbies include watching his beloved Tottenham Hotspur when he can. He was diagnosed with lung cancer in 2019, but continues to fight and enjoy life to the full.
Disclosures:
None to declare
